FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

2-Day Workshop on Generic Research Iniitiatives

FDA announces a 5/11-12 workshop entitled Fiscal Year 2023 Generic Drug Science and Research Initiatives Public Workshop.

latest-news-card-1
Medical Devices

Samsung Irregular Heart Monitor on Watch Cleared

FDA clears a Samsung Electronics 510(k) for its Irregular Heart Rhythm Notification feature on its Health Monitor app for Samsung Galaxy watches.

latest-news-card-1
Human Drugs

De Novo Marketing of 2 Covid Serology Tests

FDA grants Ortho-Clinical Diagnostics two de novo marketing authorizations for its Vitros Covid-19 serology tests.

latest-news-card-1
FDA General

Califf Warns of Regulation of Large Language Models

FDA commissioner Robert Califf warns that large language models (ChatGPT) and their use by industry will require regulation because the agency runs th...

latest-news-card-1
Human Drugs

FDA Releases Sun Non-compliance Letter

FDA posts a consent decree non-compliance letter to Sun Pharma outlining inspectional findings at the companys Mohali (Punjab), India manufacturing fa...

latest-news-card-1
Medical Devices

New Web Page on Antimicrobial Susceptibility Tests

CDRH launches a new Web page entitled Antimicrobial Resistance and Medical Devices.

latest-news-card-1
Federal Register

Guide on Quality Risk Management

Federal Register notice: FDA makes available a final guidance entitled Q9(R1) Quality Risk Management.

latest-news-card-1
Federal Register

15 Info Collections Approved by OMB

Federal Register notice: FDA posts a list of 15 information collections that have been recently approved by OMB.

latest-news-card-1
Human Drugs

Fibrogen Misses Endpoint in Roxadustat Anemia Trial

A FibroGen Phase 3 study of its anemia drug roxadustat fails to meet its primary efficacy endpoint.

latest-news-card-1
Human Drugs

FDA Issues Ajinomoto Bio-Pharma 3-item 483

FDA issues Ajinomoto Bio-Pharma Services a three-item Form FDA-483 after inspecting the firm in January.